Pure Global AI
NCT06373133Not yet recruiting

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

An Exploratory Clinical Trial of SHR-8068 Combined With Aldebelizumab and BP102 in the Treatment of Refractory Colorectal Cancer
West China HospitalPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
SHR-8068
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
West China Hospital
Timeline & enrollment
Phase
Phase 1/2
Start date
May 01, 2024
End date
Nov 01, 2026
Enrollment
36 participants
Primary outcome

Dose-limiting toxicity,PFS

Summary

To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With
 Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06373133
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06373133 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.